-
Correlation of treatment outcome in sanger/RT-qPCR KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumors with next-generation sequencing results : a single-center reportUnk, Mojca ...In patients with gastrointestinal stromal tumors (GIST), it has become mandatory to determine the driver mutation in order to predict the response to standard treatment with tyrosine kinase ... inhibitors (TKI). A total of 10‑15% of all GIST lack activating mutations in KIT proto‑oncogene, receptor tyrosine kinase (KIT)/platelet‑derived growth factor receptor alpha (PDGFRA) and have been classified as KIT/PDGFRA wild‑type (WT) GIST. They are characterized by poor response to TKI. From a group of 119 metastatic GIST patients, 17 patients with KIT/PDGFRA/BRAF WT GIST as determined by reverse transcription‑quantitative (RT‑q) PCR and Sanger sequencing were profiled by a targeted next‑gener‑ ation sequencing (NGS) approach and their treatment outcome was assessed. In the present study, 41.2% of patients as KIT/PDGFRA/BRAF WT GIST examined with RT‑qPCR and Sanger sequencing were confirmed to be carriers of patho‑ genic KIT/PDGFRA mutations by NGS and were responsive to TKI. The percentage of genuinely KIT/PDGFRA WT GIST in the present study thereby dropped from the initial 14.3% detected with the RT‑qPCR and Sanger sequencing to 7.6% after NGS. Their outcome was universally poor. The reli‑ ability of RT‑qPCR and direct Sanger sequencing results in this setting is therefore insufficient and it is recommended that NGS becomes a requirement for treatment decision at least in KIT/PDGFRA/BRAF WT GIST as determined by RT‑qPCR and Sanger sequencingVir: Oncology reports. - ISSN 1021-335X (Vol. 48, no. 3, 2022, str. 167-1-167-10)Vrsta gradiva - članek, sestavni delLeto - 2022Jezik - angleškiCOBISS.SI-ID - 118337283
Avtor
Unk, Mojca |
Bombač, Alenka |
Jezeršek Novaković, Barbara |
Stegel, Vida |
Šetrajčič Dragoš, Vita |
Blatnik, Olga |
Klančar, Gašper, 1988- |
Novaković, Srdjan
Teme
gastrointestinal stromal tumors |
imatinib |
tyrosine kinase inhibitors |
oncology |
gastrointestinalni stromalni tumorji |
imatinib |
zaviralci tirozin kinaze |
internistična onkologija
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
| Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
|---|---|---|---|---|---|---|---|---|
| JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP | |
Faktor vpliva
Baze podatkov, v katerih je revija indeksirana
| Ime baze podatkov | Področje | Leto |
|---|
| Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
|---|---|
| Unk, Mojca | 34807 |
| Bombač, Alenka | ![]() |
| Jezeršek Novaković, Barbara | 12022 |
| Stegel, Vida | 23343 |
| Šetrajčič Dragoš, Vita | 51870 |
| Blatnik, Olga | 28514 |
| Klančar, Gašper, 1988- | 34575 |
| Novaković, Srdjan | 08007 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
| Mesto prevzema | Status gradiva | Rezervacija |
|---|
Prosimo, počakajte trenutek.
